Somalogic Inc (SLGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Somalogic Inc (SLGC) has a cash flow conversion efficiency ratio of -0.043x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.36 Million) by net assets ($496.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Somalogic Inc market capitalisation for the company's overall valuation and market capitalisation.
Somalogic Inc - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how Somalogic Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Somalogic Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Somalogic Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Somalogic Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Editas Medicine Inc
NASDAQ:EDIT
|
-0.281x |
|
Delcath Systems Inc
NASDAQ:DCTH
|
0.008x |
|
Henan Qingshuiyuan Technology Co Ltd
SHE:300437
|
0.013x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
|
Hefei Gocom Information Technology Co Ltd
SHG:688367
|
0.036x |
|
Hunan Mendale Hometextile Co Ltd
SHE:002397
|
0.040x |
|
Wei Long Grape Wine Co Ltd
SHG:603779
|
-0.050x |
|
Kairuide Holding Co Ltd
SHE:002072
|
0.006x |
Annual Cash Flow Conversion Efficiency for Somalogic Inc (2019–2022)
The table below shows the annual cash flow conversion efficiency of Somalogic Inc from 2019 to 2022. View Somalogic Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $562.56 Million | $-100.67 Million | -0.179x | -196.23% |
| 2021-12-31 | $612.02 Million | $-36.97 Million | -0.060x | +60.37% |
| 2020-12-31 | $185.92 Million | $-28.34 Million | -0.152x | +93.84% |
| 2019-12-31 | $20.42 Million | $-50.54 Million | -2.475x | -- |
About Somalogic Inc
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in … Read more